ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKALAMANAO
1
Deal DateR&DClientDeal TypesStagesDeal SubjectDeal LinkSize ($M)Equity ($M)
Maximum Share (%)
ContractsPRsDeal SourceExclusivityDiseasesIndicationsTechnologiesSub TechnologiesTerritoryCompound NameMOA CategoryMechanism of ActionMolecular TargetDrug Mode of Action
Upfront Cash ($M)
Upfront Equity ($M)
Contingent Equity ($M)
R&D Support ($M)
FTE Rate ($M)Loan ($M)
Dev / Reg Milestones ($M)
Other Milestones ($M)
Total Precommercial Payments ($M)
Sales Milestones ($M)
Deal Size ($M)
Maximum Royalty (%)
Marketing Fee (%)
Transfer Price (%)
Manufacture Cost + (%)
Profit Split (%)Financial Term Explanations
2
10/2020AgeX TherapeuticsImStem BiotechnologySublicensePreclinicalIMS001 cell therapy candidate for COVID-19 and acute respiratory distress syndromeLinkYesPRNon-exclusiveInfectious-Viral, RespiratoryCoronavirus, Other RespiratoryCell Therapy - Stem Cells/Factors
3
10/2020Molecular PartnersNovartisEquity, License, OptionPreclinicalMP0420 and MP0423 DARPin therapeutics for prevent and treat COVID-19Link 231.00 YesPRInfectious-ViralCoronavirus 22.00 44.00 231.00 22.00
CHF 20 million (US$22M) | CHF 40 million (US$44M) worth of ordinary shares, at a price of CHF 23 (US$25)/share, representing 6% equity stake | CHF 150 million (US$165M), upon Novartis exercising the option to both therapeutic candidates
4
10/2020
Global Coalition for Adaptive Research
Eisai, AmgenResearchEvaluation of apremilast and eritoran in REMAP-COVID clinical studyLinkYesPRInfectious-ViralCoronavirus
5
10/2020HistogenAmerimmuneCo-Development, License, OptionPreclinicalEmricasan pan-caspase inhibitor to treat COVID-19LinkYesPRInfectious-ViralCoronavirusSyntheticsSmall Molecule
6
10/2020George Mason UniversityTargeted PharmaceuticalResearchPreclinicalPreclinical evaluation of ARDS-003 to prevent & treat COVID-19LinkYesPRInfectious-ViralCoronavirus
7
10/2020
Infectious Disease Research Institute
AmyrisLicenseRNA vaccine platform to develop COVID-19 vaccine, plus three additional indicationsLinkYesPRInfectious-Viral, UnlimitedCoronavirusVaccines
8
10/2020ADial PharmaceuticalsTodos MedicalDistribution, LicenseDiagnosticCOVID-19 point of care rapid test devicesLinkYesPRNon-exclusiveInfectious-ViralCoronavirusDiagnostics
9
10/2020ADial PharmaceuticalsAvalon GloboCareDistribution, LicenseDiagnosticCOVID-19 point of care rapid test devicesLinkYesPRNon-exclusiveInfectious-ViralCoronavirusDiagnosticsWorldwide
10
10/2020Atea PharmaceuticalsRocheCo-Development, LicensePhase IIAT-527 oral direct-acting antiviral to treat COVID-19 ex-USLink 1,000.00 YesYesSEC RedactedExclusiveInfectious-ViralCoronavirusSyntheticsSmall Molecule
Africa, Asia, Europe, Middle East, NAFTA, South America
AT-527Antiviral2019-nCoV (SARS-CoV-2) (COVID-19) 350.00 330.00 680.00 320.00 1,000.00
low double-digit to mid-twenties royalties, per Atea's IPO prospectus
11
10/2020Samsung BiologicsDiNonACSOServices to support development of DNP-019 antibody therapy. for COVID-19LinkYesPRInfectious-ViralCoronavirusMonoclonalsDNP-019Antibody2019-nCoV (SARS-CoV-2) (COVID-19)
12
10/2020McMaster UniversitySQI DiagnosticsResearchDiagnosticTechnology to measure severity of COVID-19LinkYesPRInfectious-ViralCoronavirusDiagnostics
13
10/2020Nature Technology CorporationAegis LifeLicenseNanoplasmid plasmid DNA technology and manufacturing platform for SARS-CoV-2 vaccineLinkYesPRInfectious-ViralCoronavirusVaccines
14
10/2020Entos PharmaceuticalsAegis LifeLicenseSpin out of Aegis Life to develop SARS-CoV-2 vaccine using Entos Fusogenix technologyLinkYesPRInfectious-ViralCoronavirusVaccines
15
10/2020TScan TherapeuticsPoseida TherapeuticsLicense, ResearchDiscoveryEvaluation of allogeneic T Cell receptor therapies to treat COVID-19LinkYesPRInfectious-ViralCoronavirusCell Therapy - Stem Cells/Factors
16
10/2020
Lactiga, Mount Sinai Health System
NIHResearchPreclinicalNIH funding to advance preclinical research of LCTG-001 as potential treatment for COVID-19LinkYesPRInfectious-ViralCoronavirusLCTG-001Antiviral2019-nCoV (SARS-CoV-2) (COVID-19)
17
10/2020
Yokohama City University, National Center for Global Health and Medicine, KAN Research Institute, Nagasaki University
EisaiResearchPreclinicalDevelopment of therapeutics for COVID-19, including preclinical evaluation of eritoran and E6011LinkYesPRInfectious-ViralCoronavirusMonoclonals, SyntheticsSmall Molecule
18
10/2020University of HoustonAuraVax TherapeuticsLicense, OptionIP covering intranasal vaccine technology for development of COVID-19 vaccineLinkYesPRInfectious-Viral, RespiratoryCoronavirusDrug Delivery, VaccinesNasal
19
10/2020AstraZeneca
Department of Health and Human Services, BARDA
Development, SupplyPhase IIIAZD7442 long-acting antibody combination to treat COVID-19Link 486.00 YesPRInfectious-ViralCoronavirusMonoclonals
AZD7442, AZD-8895 + AZD-1061
Antiviral2019-nCoV (SARS-CoV-2) (COVID-19) 486.00
20
10/2020Rentschler BiopharmaBioNTechSupplyPhase IIIcGMP manufacturing services for mRNA-based vaccine candidate against SARS-CoV-2LinkYesPRInfectious-ViralCoronavirusVaccines
21
10/2020YaleIsoPlexisResearchDiagnosticCOVID-19 immune profiling biomarkersLinkYesPRInfectious-ViralCoronavirusDiagnostics
22
10/2020Cobra BiologicsScancellSupplyPreclinicalProduction of plasmid to generate DNA vaccine against SARS-CoV-2LinkYesPRInfectious-ViralCoronavirusVaccines
23
10/2020FibroGenesisR4D BiotechLicensePreclinicalPneumoBlast cell therapy to treat acute respiratory distress syndrome in COVID-19 patientsLinkYesPRInfectious-Viral, RespiratoryCoronavirus, Other RespiratoryCell Therapy - Stem Cells/FactorsSouth America
24
09/2020Thermo Fisher ScientificHumanigenSupplyPhase IIIExpanded manufacturing capacity for COVID-19 therapeutic candidate lenzilumabLinkYesPRInfectious-ViralCoronavirusMonoclonals
25
09/2020IriSysTFF PharmaceuticalsSupplyInhalable lung medication with potential to treat COVID-19 and invasive pulmonary aspergillosisLinkYesPRInfectious-Viral, RespiratoryCoronavirusDrug DeliveryOther
26
09/2020Clene Nanomedicine
Tottenham Acquisition, Chelsea Worldwide
AcquisitionPhase IIIReverse merger agreement, combined public company to be named Clene IncLinkYesPR
Central Nervous System, Infectious-Viral
Alzheimer's Disease, Coronavirus, Multiple Sclerosis, Parkinson's Disease
27
09/2020Purdue UniversityPhysIQResearchAlgorithms to detect early signs of COVID-19 from biometric smartwatch dataLinkYesPRInfectious-ViralCoronavirus
28
09/2020
BioSig Technologies, ViralClear Pharmaceuticals
Sorrento TherapeuticsResearchEvaluation of small molecule and antibody combination therapies against COVID-19LinkYesPRInfectious-ViralCoronavirusMonoclonals, Synthetics
29
09/2020ABECSerum Institute of IndiaSupplyManufacture of NVX-CoV2373 COVID-19 vaccine candidateLinkYesPRInfectious-ViralCoronavirusVaccines
COVID-19 vaccine, NVX-CoV2373
VaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)
30
09/2020BachemNeuroRx, Relief TherapeuticsSupplyManufacture of RLF-100 (aviptadil) drug substance for COVID-19 infection with respiratory failureLinkYesPRInfectious-Viral, RespiratoryCoronavirus, Other RespiratoryPeptidesInvicorp, aviptadil, RLF-100Peptide Hormone
vasoactive intestinal peptide receptor agonists
31
09/2020Lumen Bioscience
US Army Medical Research and Development Command
Research$4M grant to develop nanobody-based Covid-19 therapeuticLink 4.00 YesPRInfectious-ViralCoronavirusMonoclonals 4.00
32
09/2020
Grand River Aseptic Manufacturing
Johnson & Johnson, JanssenSupplyTechnical transfer and fill and finish manufacture of SARS-CoV-2 vaccine candidateLinkYesPRInfectious-ViralCoronavirusVaccines
33
09/2020
Endo International, Par Sterile Products
NovavaxSupplyFill-finish manufacturing services for NVX-CoV2373 COVID-19 vaccine candidateLinkYesPRInfectious-ViralCoronavirusVaccines
COVID-19 vaccine, NVX-CoV2373
VaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)
34
09/2020NovartisBioNTechAsset PurchaseGMP certified manufacturing facility in Germany to expand COVID-19 vaccine production capacityLinkYesPRInfectious-ViralCoronavirusVaccines
35
09/2020List Biological LaboratoriesBetterLife PharmaSupplyPhase IIManufacture of AP-003 interferon alpha 2b to treat COVID-19LinkYesPRInfectious-ViralCoronavirusRecombinant DNAAP-003Antiviralinterferon alpha 2b (IFNa2b)Inhibitor
36
09/2020ZymeworksImmunoPrecise AntibodiesLicense, ResearchAzymetric and EFECT platforms to develop SARS-CoV-2 antibody against COVID-19LinkYesPRInfectious-ViralCoronavirusMonoclonals
37
09/2020LonzaHumanigenSupplyPhase IIIManufacture of Lenzilumab COVID-19 candidateLinkYesPRInfectious-ViralCoronavirusMonoclonalslenzilumab, KB003Antiviral
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA) (GMR) (CD116) (GM-CSF-R-alpha)
38
09/2020IncellDxMD BiosciencesLicenseDiagnosticCOVID-19/cytokine storm cytokine panel and CCR5 receptor occupancy in the US and EULinkYesPRInfectious-ViralCoronavirusDiagnosticsEurope, NAFTA
39
09/2020Dynavax TechnologiesValnevaSupplyCpG 1018 adjuvant for use in VLA2001 SARS-CoV-2 vaccine candidateLinkYesPRInfectious-ViralCoronavirusAdjuvant, VaccinesVLA2001VaccineInactivated2019-nCoV (SARS-CoV-2) (COVID-19)
40
09/2020HiFiBiOABL BioCo-Development, LicensePreclinicalHFB30132A SARS-CoV-2 neutralizing antibody for COVID-19LinkYesPRInfectious-ViralCoronavirusMonoclonalsHFB30132A, HFB-3013Antiviral2019-nCoV (SARS-CoV-2) (COVID-19)Inhibitor
41
09/2020Vaxess TechnologiesMedigen Vaccine BiologicsDevelopment, LicenseFormulationMIMIX patch system to deliver COVID-19 and quadrivalent seasonal influenza vaccineLinkYesPRInfectious-ViralCoronavirus, InfluenzaDrug Delivery, VaccinesTransdermal
42
09/2020ArctorisSyntekabioLetter of Intent, License, ResearchDiscoveryAI-driven drug discovery to assess small molecule therapeutics for COVID-19LinkYesPRInfectious-ViralCoronavirusScreening, SyntheticsSmall Molecule
43
09/2020Aditx TherapeuticsSalveo DiagnosticsLicenseDiagnosticAditxtScore Platform for COVID-19 to detect antibodies against SARS-CoV-2 antigensLinkYesPRInfectious-ViralCoronavirusDiagnostics
44
09/2020Thermo Fisher ScientificInovio PharmaceuticalsLetter of Intent, SupplyManufacture of INO-4800 DNA COVID-19 vaccine candidateLinkYesPRInfectious-ViralCoronavirusVaccinesINO-4800VaccineDNA2019-nCoV (SARS-CoV-2) (COVID-19)
45
09/2020Relation TherapeuticsBill & Melinda Gates FoundationResearchGrant to support machine learning to identify repurposed drug combinations for COVID-19Link 1.30 YesPRInfectious-ViralCoronavirus 1.30
46
09/2020MicroGEMNIHDevelopmentDiagnosticFunding to support development of fast-track rapid, no-lab COVID-19 saliva testLink 40.90 YesPRInfectious-ViralCoronavirus, InfluenzaDiagnostics 40.90
47
08/2020Serum Institute of India
GAVI the Vaccine Alliance, Bill & Melinda Gates Foundation
Supply100 million doses of COVID-19 vaccines for low-income countries, expanded to 200 million dosesLink 300.00 YesPRInfectious-ViralCoronavirusVaccines 300.00
48
08/2020FioRelay MedicalJoint VentureDiagnostic, DeviceJoint venture to accelerate adaption of Fionet data-and-device platform for COVID-19 testingLinkYesPRInfectious-ViralCoronavirusDiagnostics
49
08/2020AllStar Health BrandsTPT Global TechDistributionDiagnosticQuikLAB Rapid Covid-19 Testing Lab ModulesLinkYesPRNon-exclusiveInfectious-ViralCoronavirusDiagnosticsNAFTA, South America
50
08/2020NOWDiagnostics
Department of Health and Human Services, BARDA
DevelopmentDiagnosticADEXUSDx COVID-19 rapid antibody testLinkYesPRInfectious-ViralCoronavirusDiagnostics
51
08/2020HumaneticsPharmaceutics InternationalResearchClinical evaluation of BIO 300 in COVID-19 patientsLinkYesPRInfectious-Viral, RespiratoryCoronavirusBIO 300, genistein nanoparticleapoptosis, protein tyrosine kinase (PTK)Inhibitor
52
08/2020IriSysQualigenSupplyPreclinicalManufacture of AS1411 drug product to treat viral diseases including COVID-19LinkYesPRInfectious-ViralCoronavirus
AS1411, ACT-GRO-777, AGRO-100
DNA/RNA DisruptionapoptosisStimulant
53
08/2020SugentechAvellino LabsDistribution, LicenseDiagnosticCOVID-19 rapid diagnostic serology test and ELISA to detect COVID-19 antibodiesLinkYesPRInfectious-ViralCoronavirusDiagnostics
54
08/2020Sinovac BiotechBio FarmaLicense, SupplyPhase IIICoronaVac inactivated vaccine candidate against COVID-19LinkYesPRInfectious-ViralCoronavirusVaccinesCoronaVacVaccineInactivated2019-nCoV (SARS-CoV-2) (COVID-19)
55
08/2020HarvardAbbVieResearchEmergent viral disease research with focus on coronavirus and viruses that lead to hemorrhagic feverLink 30.00 YesPRInfectious-ViralCoronavirusMonoclonals, SyntheticsSmall Molecule 30.00 30.00
56
08/2020NantKwestImmunityBioCo-Development, LicenseCOVID-19 therapeutics and vaccine candidatesLinkYesPRInfectious-ViralCoronavirusCell Therapy - Stem Cells/Factors, Vaccines
57
08/2020CytoSorbentsTerumoDistribution, LicenseDeviceCytoSorb extracorporeal cytokine adsorber for use in critically ill COVID-19 patientsLinkYesPRInfectious-ViralCoronavirusDevice
58
08/2020Avid BioservicesOragenicsSupplyCDMO services to support development of Terra CoV-2 vaccine candidate for COVID-19LinkYesPRInfectious-ViralCoronavirusVaccines
59
08/2020Regeneron PharmaceuticalsRocheCo-Development, DistributionPhase IIIDistribution of REGN-COV2 anti-viral antibody cocktail to prevent and treat COVID-19 outside the USLinkYesPRInfectious-ViralCoronavirusMonoclonals
REGN-COV2, REGN-10933+ REGN-10987
Antiviral2019-nCoV (SARS-CoV-2) (COVID-19)
Companies will jointly fund and execute certain ongoing clinical studies. Roche will be responsible for distribution outside the U.S.
60
08/2020
Utrecht University, Harbour BioMed, Erasmus
Viroclinics Biosciences, Kiadis Pharma
DevelopmentMonoclonal antibody and natural killer cell combination therapy to treat COVID-19LinkYesPRInfectious-ViralCoronavirus
Cell Therapy - Stem Cells/Factors, Monoclonals
61
08/2020BioSymetricsJohnson & Johnson, JanssenResearchContingent-AI machine learning to predict onset and severity of COVID-19 in different populationsLinkYesPRInfectious-ViralCoronavirus
62
08/2020Aragen Bioscience
NorthStar Medical Radioisotopes, Monopar Therapeutics
CROCRO services to select uPRIT lead candidate to advance into IND-enabling development for COVID-19LinkYesPRInfectious-ViralCoronavirus
63
08/2020
Indiana Biosciences Research Institute
BioMEMs AnalyticsLicenseDiagnosticBioMEMs and SIERRA Reagent to diagnose COVID-19 and other infectious diseasesLinkYesPRInfectious-ViralCoronavirusDiagnostics
64
08/2020Generex BiotechnologyBintai KindenLetter of Intent, LicenseIi-Key-SARS-CoV-2 vaccine for COVID-19 in MalaysiaLinkYesPRInfectious-ViralCoronavirusVaccinesAsia
65
08/2020TherapureVBI VaccinesSupplyManufacture of vaccine drug substance for coronavirus vaccine candidatesLinkYesPRInfectious-ViralCoronavirusVaccines
66
08/2020Arcturus TherapeuticsIsraeli Ministry of HealthSupplyARCT-021 STARR mRNA vaccine candidate for COVID-19LinkYesPRInfectious-ViralCoronavirusVaccinesMiddle East
ARCT-021, LUNAR-COV19, LUNAR-COVID19
VaccinemRNA2019-nCoV (SARS-CoV-2) (COVID-19)
67
08/2020George Washington UniversityHoth TherapeuticsLicense, WarrantDiagnostic, DeviceDevice to detect the presence of SARS-CoV-2LinkYesSEC RedactedExclusiveInfectious-ViralCoronavirusDevice, DiagnosticsWorldwide
72.5K warrants @ $2.76/sh, per Hoth's 6Q20 | mid single-digit royalty, per Hoth's 6Q20
68
08/2020CytoSorbentsSurgical PartnersDistribution, LicenseDeviceCytoSorb extracorporeal cytokine adsorber for use in COVID-19 patients with respiratory failureLinkYesPRInfectious-Viral, RespiratoryCoronavirusDevice
69
08/2020CytoSorbentsInvoSurgDistribution, LicenseDeviceCytoSorb extracorporeal cytokine adsorber for use in COVID-19 patients with respiratory failureLinkYesPRInfectious-Viral, RespiratoryCoronavirusDevice
70
08/2020
Coronavirus Immunotherapy Consortium
HiFiBiOResearchDiscoveryEvaluation of neutralizing antibodies against SARS-CoV-2LinkYesPRInfectious-ViralCoronavirusMonoclonals
71
08/2020
Centers for Disease Control, Department of Defense, Department of Health and Human Services
McKessonDistributionCOVID-19 vaccine distribution to support Operation Warp SpeedLinkYesPRInfectious-ViralCoronavirusVaccines
72
08/2020Columbia UniversityIsoPlexisResearchSingle-Cell Secretome immune profiling solutions to advance COVID-19 vaccine developmentLinkYesPRInfectious-ViralCoronavirusVaccines
73
08/2020BioHit HealthcareThermoGenesisSupplyDiagnosticSARS-CoV-2 IgM/IgG Antibody Test KitLinkYesYesSEC RedactedNon-exclusiveInfectious-ViralCoronavirusDiagnostics
74
08/2020SK bioscienceNovavaxSupplyManufacture of antigen component of NVX-CoV2373 COVID-19 vaccine candidateLinkYesPRInfectious-ViralCoronavirusVaccines
COVID-19 vaccine, NVX-CoV2373
VaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)
75
08/2020TFF PharmaceuticalsUNION therapeuticsLicense, OptionFormulationThin Film Freezing technology to develop dry powder formulations of niclosamide for COVID-19Link 210.00 YesPRExclusiveInfectious-ViralCoronavirusDrug DeliveryOtherWorldwide
niclosamide, ANA-001, BAY 2353, NSC-178296, WR 46234
Antiviral
signal transducer and activator of transcription 3 (STAT3)
Inhibitor 210.00
Tiered single-digit royalties | $210M in development, regulatory and sales milestones
76
08/2020GenScript BiotechBeroni GroupServicesCDMO platform to advance study to develop nanobodies to treat COVID-19LinkYesPRInfectious-ViralCoronavirus
77
08/2020QuotientANA TherapeuticsSupplyManufacture of Niclosamide for COVID-19 pivotal clinical trialsLinkYesPRInfectious-ViralCoronavirusSyntheticsSmall Molecule
niclosamide, ANA-001, BAY 2353, NSC-178296, WR 46234
Antiviral
signal transducer and activator of transcription 3 (STAT3)
Inhibitor
78
08/2020IsoTherapeutics
NorthStar Medical Radioisotopes, Monopar Therapeutics
SupplyManufacture of radio-immuno-therapeutic to treat severe COVID-19LinkYesPRInfectious-ViralCoronavirusMonoclonalsConjugates
79
08/2020PfizerGileadSupplyApprovedManufacture of remdesivir to treat COVID-19LinkYesPRInfectious-ViralCoronavirusSyntheticsSmall MoleculeVeklury, remdesivir, GS-5734Antiviral
replicase polyprotein 1ab, RNA-directed RNA polymerase L
Inhibitor
80
08/2020ADial PharmaceuticalsBrikDistributionDiagnosticRapid Result COVID-19 antibody test kitLinkYesPRInfectious-ViralCoronavirusDiagnostics
81
08/2020NovavaxSerum Institute of IndiaDistribution, License, SupplyNVX-CoV2373 COVID-19 vaccine candidate in low- and middle-income countries and IndiaLinkYesPRExclusiveInfectious-ViralCoronavirusAdjuvant, VaccinesAsia
COVID-19 vaccine, NVX-CoV2373
VaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)
82
08/2020Aegea BiotechnologiesBioceptCo-Development, License, OptionDiagnosticPCR-based COVID-19 assay utilizing Switch-Blocker technologyLinkYesPRInfectious-ViralCoronavirusDiagnostics
83
08/2020
Shenzhen Kangtai Biological Products
AstraZenecaSupplyManufacture of AZD1222 COVID-19 vaccineLinkYesPRInfectious-ViralCoronavirusVaccines
COVID-19 vaccine, ChAdOx1, AZD1222
VaccineNonreplicating Viral Vector2019-nCoV (SARS-CoV-2) (COVID-19)
84
08/2020Johnson & Johnson, Janssen
Department of Health and Human Services, Department of Defense, BARDA
Supply100 million doses of Ad26.COV2.S vaccine against COVID-19LinkYesPRInfectious-ViralCoronavirusVaccinesAd26.COV2-S, Ad26.COV2.SVaccineRecombinant2019-nCoV (SARS-CoV-2) (COVID-19)
85
08/2020BioNTech, PfizerPublic Health Agency of CanadaSupplyPhase IIBNT162 mRNA-based vaccine candidate against COVID-19LinkYesPRInfectious-ViralCoronavirusVaccinesNAFTABNT162VaccinemRNA2019-nCoV (SARS-CoV-2) (COVID-19)
86
08/2020Todos MedicalPathnova LaboratoriesDistribution, LicenseDiagnosticCOVID-19 and breast cancer tests in Singapore and Southeast AsiaLinkYesPRCancer, Infectious-ViralBreast, CoronavirusDiagnosticsAsia
87
07/2020Regeneron Pharmaceuticals
Department of Health and Human Services, Department of Defense, BARDA
SupplyPhase IIManufacture of REGN-COV2 antibody cocktail to treat COVID-19 under Warp Speed ProgramLink 450.00 YesPRInfectious-ViralCoronavirusMonoclonals
REGN-COV2, REGN-10933+ REGN-10987
Antiviral2019-nCoV (SARS-CoV-2) (COVID-19) 450.00
88
07/2020ValnevaUK GovernmentSupply60 million doses of VLA2001 SARS-CoV-2 vaccine candidate for COVID-19LinkYesPRInfectious-ViralCoronavirusAdjuvant, VaccinesVLA2001VaccineInactivated2019-nCoV (SARS-CoV-2) (COVID-19)
89
07/2020Humanetics
NIH, National Institute of Allergy and Infectious Diseases
ResearchFunding to support testing of BIO 300 in COVID-19 patientsLinkYesPRInfectious-Viral, RespiratoryCoronavirusBIO 300, genistein nanoparticleapoptosis, protein tyrosine kinase (PTK)Inhibitor
90
07/2020SmartPharmSorrento TherapeuticsAcquisition, Letter of IntentAcquisition for undisclosed termsLinkYesPRCancer, Infectious-ViralBroad Focus Cancer, Coronavirus
91
07/2020NIHHumanigenCROPhase IILenzilumab in a COVID clinical trialLinkYesYesSEC FullInfectious-ViralCoronavirusMonoclonalslenzilumab, KB003Antiviral
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA) (GMR) (CD116) (GM-CSF-R-alpha)
92
07/2020CytoDynAmerican ReagentDistributionPhase IIPRO140 (leronlimab) for the treatment of COVID-19 in USLinkYesSEC RedactedExclusiveInfectious-ViralCoronavirusMonoclonalsHumanized AbsNAFTA
leronlimab, PRO 140, PA-14, WHO 10751, PRO140
Antiviral
anti-CCR5 humanized IgG4 monoclonal antibody inhibitor
CC chemokine receptor type 5 (CCR5) (CD195)
Antagonist
93
07/2020Emery PharmaHalodineCROCRO services to support development of oral and nasal antiseptics active against COVID-19LinkYesPRInfectious-ViralCoronavirus
94
07/2020Becton Dickinson
Department of Defense, Department of Health and Human Services
SupplyDiagnosticFunding to scale up US manufacturing of BD Veritor Solution for Rapid Detection of SARS-CoV-2Link 24.00 YesPRInfectious-ViralCoronavirusDiagnostics 24.00
95
07/2020PrecipioADS BiotecDistributionDiagnosticCOVID-19 serology antibody testsLinkYesPRInfectious-ViralCoronavirusDiagnostics
96
07/2020Medigen BiotechAlercellDistributionDiagnosticCOVID-19 rapid antibody serology testsLink 280.00 YesPRInfectious-ViralCoronavirusDiagnostics 280.00
97
07/2020BioNTech, Pfizer
Ministry of Health, Labour and Welfare (Japan)
Supply120 million doses of BNT162 mRNA-based vaccine candidate against COVID-19LinkYesPRInfectious-ViralCoronavirusVaccinesAsiaBNT162VaccinemRNA2019-nCoV (SARS-CoV-2) (COVID-19)
98
07/2020IntravaccCelonic AGResearchPreclinicalCOVID-19 vaccine combining immunogenic Spike (S) protein of SARS-CoV-2 and OMV technologyLinkYesPRInfectious-ViralCoronavirusVaccines
99
07/2020Mesa BiotechNIHDevelopmentDiagnosticFunding to support development of Accula SARS-CoV-2 Test (RADx Program)Link 15.40 YesPRInfectious-ViralCoronavirusDiagnostics 15.40
100
07/2020HelixNIHDevelopmentDiagnosticFunding to support rapid scaling of end-to-end COVID-19 test system (RADx Program)Link 33.40 YesPRInfectious-ViralCoronavirusDiagnostics 33.40